DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • China
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
600201 logo

Jinyu Bio-technology Co., Ltd. Stock Price

SHSE:600201 Community·CN¥12.7b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

600201 Share Price Performance

CN¥0
-8.23 (-100.00%)
​
CN¥0
-8.23 (-100.00%)
​
Price CN¥0
Fri, 11 Sep 26
Share Pricen/a

600201 Community Narratives

There are no narratives available yet.
Create Narrative
There are no community narratives available.

Trending Discussion

No trending discussion available.

Recently Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Excellent balance sheet with reasonable growth potential.

1 Risk
2 Rewards
View Full Analysis

Jinyu Bio-technology Co., Ltd. Key Details

CN¥1.5b

Revenue

CN¥726.6m

Cost of Revenue

CN¥806.6m

Gross Profit

CN¥662.9m

Other Expenses

CN¥143.8m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
0.13
52.61%
9.38%
1.8%
View Full Analysis

About 600201

Founded
1992
Employees
1881
CEO
Jing Zhang
WebsiteView website
www.jinyu.com.cn

Jinyu Bio-technology Co., Ltd. engages in the research and development, production, and sale of veterinary biological products in China and internationally. The company’s products focus on preventing porcine mycoplasmal pneumonia, pseudorabies, highly pathogenic avian influenza, brucellosis, and other Class I, II, and III animal diseases. It also provides pig vaccines, swine foot-and-mouth disease type O and A bivalent inactivated, porcine circovirus type 2 baculovirus vector inactivated, porcine reproductive and respiratory syndrome chimeric virus live and inactivated, and swine fever live, transmissible gastroenteritis in pigs, swine live influenza bivalent, bovine viral diarrhea/mucosal disease, infectious rhinitis two-dose inactivated, brucella gene-deleted live, brucellosis live, inactivated emphysema and gangrene, ruminant disease live, newcastle disease, infectious bursal disease trivalent inactivated, recombinant avian influenza virus trivalent inactivated, infectious bronchitis symptoms, egg drop syndrome type 4 quadrivalent inactivated infectious bronchitis, canine distemper and parvovirus bivalent live, feline panleukopenia calicivirus disease trivalent inactivated trivalent, and inactivated rabies vaccines. Further, the company manufactures and sells biological pharmaceutical preparations, and chemical reagents and auxiliaries; develops biotechnology; transfer and consulting services; advanced medical equipment and instruments; import and export of goods and technology; and provision of property management services. Additionally, it is involved in real estate activities; biochemical products; planting; hotel management services; internet information service finance; biotechnology promotion services; owner-owned house for rent; mechanical equipment processing; investment management; management, meal, technical, and medical services; and trading activities. Jinyu Bio-technology Co., Ltd. was founded in 1992 and is based in Hohhot, China.

Recent 600201 News & Updates

Recent updates

No updates

Jinyu Bio-technology Co., Ltd. Competitors

603259 logo

WuXi AppTec

Symbol: SHSE:603259
Market cap: CN¥449.1b
600276 logo

Jiangsu Hengrui PharmaceuticalsLtd

Symbol: SHSE:600276
Market cap: CN¥281.1b
688506 logo

Sichuan Biokin PharmaceuticalLtd

Symbol: SHSE:688506
Market cap: CN¥98.5b
000538 logo

Yunnan Baiyao GroupLtd

Symbol: SZSE:000538
Market cap: CN¥89.9b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide